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Research  on nanoparticles  has created  interest  among  the  biomedical  scientists.  Nanopar-
ticle  conjugation  aims  to target  drug  delivery,  increase  drug  efﬁcacy  and imaging  for  better
diagnosis.  Toxicity  proﬁle  of the  nanoconjugated  molecules  has  not  been  studied  well. In
this communication,  the  toxicity  proﬁle  of snake  venom  cytotoxin  (NKCT1),  an  antileukemic
protein  toxin,  was  evaluated  after  its conjugation  with  gold  nanoparticle  (GNP-NKCT1).
Gold  nanoparticle  conjugation  with  NKCT1  was  done  with  NaBH4 reduction  method.  The
conjugated  product  GNP-NKCT1  was  found  less  toxic  than  NKCT1  on  isolated  rat  lympho-
cyte, mice  peritoneal  macrophage,  in culture,  which  was  evident  from  the  MTT/Trypan  blue
assay. Peritoneal  mast  cell  degranulation  was  in the  order  of  NKCT1  >  GNP-NKCT1.  The  in
vitro cardiotoxicity  and  neurotoxicity  were  increased  in case  of  NKCT1  than  GNP-NKCT1.
On  isolated  kidney  tissue,  NKCT1  released  signiﬁcant  amount  of  ALP  and  -GT  than  GNP-
NKCT1.  Gold  nanoconjugation  with  NKCT1  also  reduced  the lethal  activity  in  mice.  In vivo
acute/sub-chronic  toxicity  studies  in  mice  showed  signiﬁcant  increase  in  molecular  mark-
ers due  to  NKCT1  treatment,  which  was  reduced  by  gold  nanoconjugation.  Histopathology
study  showed  decreased  toxic effect  of  NKCT1  in  kidney  tissue  after  GNP  conjugation.  The
present  study  conﬁrmed  that  GNP  conjugation  signiﬁcantly  decreased  the  toxicity  proﬁle
of NKCT1.  Further  studies  are  in  progress  to  establish  the molecular  mechanism  of GNP
induced toxicity  reduction.
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1. Introduction
Venom and toxins from the faunal and ﬂoral com-
munity of this world hold promise as medicinal agents
that have been mentioned in ancient literatures Ayurvada,
Unani, homoeopathy. Calmette [1] ﬁrst showed that snake
(Naja  sp.) venom possesses anticancer potential. Many
∗ Corresponding author. Tel.: +91 33 23508386/6387/6396/1397x229;
fax:  +91 33 2351 9755/2241 3288.
E-mail addresses: agomescu@gmail.com, gomesantony@hotmail.com
(A. Gomes).
http://dx.doi.org/10.1016/j.toxrep.2014.04.007
2214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. Th
(http://creativecommons.org/licenses/by-nc-nd/3.0/).ished  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
reports are available on the therapeutic potential of venom
and  toxins against experimental pathophysiological condi-
tions  [2,3]. drCT-1, a protein toxin isolated from the snake
Daboia  russelii venom, NKCT1 puriﬁed from Indian mono-
cellate cobra (Naja kaouthia) venom and NN-32 isolated
from snake (Naja naja) venom, showed anti-cancer activity
[3–5].  N. kaouthia venom showed antiarthritic potential in
experimental animal model [2]. Crototoxin isolated from
Crotelus  durisus terriﬁcus venom has anticancer activity
against human and murine tumour cell line [6]. VRCTC-
310  produced by the combination of two different puriﬁed
snake  venom proteins also possesses anticancer activity
[7].  Cobra toxin, isolated from snake Naja naja atra venom,
is is an open access article under the CC BY-NC-ND license
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light conditions (12 h light and dark cycle) and relative
humidity (65 ± 5%). The animals were provided with pel-P.P. Saha et al. / Toxic
as antinociceptive activity in mice. It has been found that
re-treatment with cobra venom factor delayed the acute
nﬂammation of chronic arthritis in rat model. It depleted
at  complement protein C3 and inhibited the inﬂamma-
ory response in adjuvant induced arthritis [8]. One of the
ajor  drawbacks of these bioactive molecules is their tox-
city,  which does not allow them to proceed further in
rug  development process. In order to overcome the tox-
city,  several attempts have been made including liposome
ncapsulation, silica coating, nanoconjugation, etc. [9,10].
Nanotechnology tunes the physical and chemical prop-
rties  of a substance at molecular level, uses materials
nd devices designed to interact with the body at sub-
ellular/tissue speciﬁc level with an aim to have maximum
herapeutic and minimum adverse effects [11]. Use of
anotechnology against cancer, cardiac, neurodegenera-
ive and inﬂammatory disorders was already reported.
vidences in synthesis and functionalization of nanopar-
icles have brought attention in the ﬁeld of biomedical
pplications including imaging, drug delivery, sensing of
arget  molecules [12].
Application  of nanotechnology in the ﬁeld of toxi-
ology has increased the efﬁcacy of the bioactive toxin
olecules [13]. Mellitin, from bee venom, is a potential
andidate for anticancer therapy, having disadvantages
ike nonspeciﬁcity and unfavourable pharmacokinetics.
oman and co-workers conjugated mellitin in the outer
ipid  monolayer of perﬂurocarbon (PFC) nanoparticles. The
anocarrier  allows selective deliverance of mellitin to mul-
iple  tumour targets without apparent sign of toxicity
14]. Bombesin peptide obtains from toad skin showed
rotective activity against prostate, breast, and small cell
ung  carcinoma in experimental studies. It was conjugated
ith gold nanoparticle (GNP), which increased its afﬁnity
owards gastrin releasing peptide (GRP) receptors, over-
xpressed on tumour cells. Bombesin–gold conjugation
lso showed reduced reticulo-endothelium system uptake
y  organs with concomitant increase in uptake at tumour
argets, which reduced its toxic manifestation towards the
ells,  other than the tumour tissue [15].
Gomes et al. [2] showed that N. kaouthia venom (NKV)
ad antiarthritic potential in experimental animals. A pro-
ein  toxin NKCT1 isolated from NKV possesses anticancer
ctivity [3]. Although it offered beneﬁcial effects against
xperimental pathophysiological conditions, toxicity of
KCT1  was also reported [16]. Recently Bhowmik et al.
9]  conjugated the protein toxin NKCT1 with PEGylated
old nanoparticles by using NaBH4 reduction technique,
hich increased the anticancer property of NKCT1. How-
ver,  the toxicity of nanogold conjugated NKCT1 needs to
e  assessed for its safety evaluation. The present study was
n  effort to investigate the toxicity proﬁle of GNP-NKCT1
olecule through in vivo and in vitro study.
. Materials and methods
.1.  ChemicalsChemicals and reagents used were of analytic grade. The
ollowing chemicals were used – acrylamide (SRL, India);
mmonium persulphate (SRL, India); bisacrylamide (SRL,ports 1 (2014) 74–84 75
India);  bromophenol blue (Merck, India); carboxymethyl
cellulose (Sigma, USA); creatine kinase, brain and muscle
isoenzyme (CK-MB) kit (Ecoline, Merck, India); coomassie
brilliant blue (Sigma, USA); disodium hydrogen phosphate
(SRL,  India); drabkin solution (Cogent, India); Diastix-
Reagent Strips (Merck, India); EDTA (SRL, India); eosin
(Qualigen, India); folin ciocalteu reagent (SRL, India);
glycine (SRL, India); HAuCl4 (Sigma, USA); haematoxylin
(Qualigen, India); histopaque (Sigma, USA); KCl (SRL,
India); Lactate dehydrogenase (LDH) kit (Merck, India); mer-
captoethanol (SRL, India); methylene blue (Merck, India);
MTT  (Sigma, USA); NaBH4 (SRL, India); P-nitrophenyl
phosphate (SRL, India); poly(ethylene)glycol (SRL, India);
RPMI-1640 medium (GIBCO, USA); TRIS (SRL, India); SDS
(Merck,  India); Serum glutamic oxaloacetic transaminase
(SGOT)/serum glutamic pyruvic transaminase (SGPT) kit
(Merck,  India); sodium dihydrogen phosphate (SRL, India);
sodium  lauryl sulphate (SRL, India); TEMED (Merck, India);
and  urea kit (Merck, India).
2.2.  Puriﬁcation of NKCT1
Lyophilized  N. kaouthia venom was collected from Cal-
cutta  Snake Park, Kolkata, India. Venom concentration was
expressed  in terms of dry weight/protein equivalent [17].
NKCT1  was puriﬁed from NKV by ion exchange chro-
matography and HPLC as reported earlier [3]. The fraction
was  desalted and concentrated by Centricon (Millipore
MWCO  3k). Homogeneity of NKCT1 was  checked by SDS-
polyacrylamide gel electrophoresis (PAGE) method [18].
2.3.  Synthesis of GNP-NKCT1
The  gold nanoparticles were prepared by sodium boro-
hydrate reduction method [9] with modiﬁcation. 200 l
HAuCl4 (20 mM)  and 10 l PEG (10 mg  ml−1) were mixed
with 800 l of sterile phosphate buffer (10 mM,  pH 7.2).
Then 40 l of NaBH4 (100 mM)  was  added drop wise and
stirred at 37 ◦C for 1 h. Just after mixing the NaBH4, the
colour of the reaction mixture was light violet and after
several minutes, it changed to deep blue. After 1 h of stir-
ring,  mixture was kept in room temperature for 24 h. After
that  832 l protein toxin NKCT1 (1 mg  ml−1) was  added
into the reaction mixture and the suspension was kept at
room  37 ◦C for conjugation.
2.4.  Experimental animals
Swiss  albino male mice (20 ± 2 g), Wister male albino
rats (120 ± 10 g), male guinea pig (250 ± 10 g), and toad
(80  ± 5 g) were obtained from the approved animal breed-
ers  of University of Calcutta, and kept in polypropylene
cage at controlled temperature (25 ± 2 ◦C), with suitablelet  diet and water ad libitum. The animal experiments were
conducted with prior approval from the Animal Ethics
Committee, Dept. of Physiology, University of Calcutta (AEC
Ref:  820/04/ac/CPC SEA. 2010, dated: 16.11.2011).
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2.5. Collection and culture of rat blood lymphocyte
Blood was collected aseptically from the male albino
Wister rats (120 ± 10 g) by cardiac puncture and trans-
ferred to heparinized vial. Lymphocytes were collected
from the whole blood using Ficoll histopaque after proper
dilution with sterile saline water. It was washed with PBS
and  cultured RPMI-1640 media. Cells were grown in a CO2
Incubator at 37 ◦C with 5% CO2 in humidiﬁed condition.
2.6. Collection and culture of mouse peritoneal
macrophage
1 ml  of 20% starch solution (w/v, ratio) was injected (i.p.)
to  male albino Swiss mice (20 ± 2 g). After 24 h, peritoneal
ﬂuid was aseptically collected and diluted with normal
saline. Peritoneal macrophage was washed with PBS and
cultured  in RPMI-1640 at 37 ◦C with 5% CO2 in humidiﬁed
condition.
2.7. In vitro cellular toxicity study
2.7.1. Effect on rat lymphocyte and mouse peritoneal
macrophage
Isolated rat blood lymphocytes (1 × 106) and mouse
peritoneal macrophage (1 × 106) were seeded in 96 well
plate  and treated with NKCT1 (2 g ml−1)/GNP-NKCT1
(2 g ml−1). MTT  assay was done to conﬁrm its cytotoxic
effect [36]. After 18 h of incubation, 40 l (5 mg  ml−1) of
MTT  solution was added and kept for another 4 h. The
formazan granules formed by viable cells were dissolved
in  DMSO and the O.D. at 570 nm was measured with an
ELISA  reader (BioTek, ELx800). The cell growth inhibition
studies were done by 0.2% trypan blue exclusion assay
with  direct count using haemocytometer counting cham-
ber  under light microscope (Olympus, Tokyo).
2.7.2. Effect on rat peritoneal mast cells
Peritoneum was collected from male albino Wistar rats.
The  omentum was placed in different watch glasses group
1:  0.5 ml  normal saline (control), group 2: 0.5 ml  normal
saline and NKCT1 (2 g ml−1) and group 3: 0.5 ml  nor-
mal  saline and GNP-NKCT1 (2 g ml−1). It was incubated
at 37 ◦C for 30 min. After incubation, the peritoneum from
each  group was  put on clear glass slide in perfectly stretch-
ing  condition and was ﬁxed over ﬂame. The slide was
then  treated with ethanol:chloroform:acetic acid (6:3:1)
mixture for 15 min. After downgrading treatment with
ethanol:water, the slides were stained with 0.1% aqueous
toluidine blue. The excess stain was washed with distilled
water and upgrading treatment with ethanol:water up to
100%  ethanol. The slides were washed twice with xylene
and  mounted in DPX. The mast cell count was done under
the  light microscope and expressed in terms of % degranu-
lation against control preparation [19].
2.8. In vitro organ/tissue toxicity study2.8.1. Effect on isolated guinea pig heart and auricle
Isolated guinea pig heart was prepared after Langen-
dorff [20] and perfused with oxygenated (95% O2 + 5% CO2)ports 1 (2014) 74–84
Tyrode’s  solution (NaCl 137 mM,  KCl 2.7 mM,  CaCl2·2H2O
2.6  mM,  MgCl2·6H2O 1.27 mM,  NaHCO3 11.9 mM,  NaH2PO4
0.4 mM and glucose 5.5 mM)  containing double dextrose
(2  g l−1) and the temperature was  maintained at 37 ± 1 ◦C.
The  preparation was treated with NKCT1 (2 g ml−1)/GNP-
NKCT1 (2 g ml−1) and contraction was recorded on a
rotating smoked drum using a heart lever. Isolated guinea
pig  auricle was prepared after Burn [21] and suspended
in oxygenated Tyrode’s solution (29 ± 1 ◦C) in a 4 ml
glass bath. The preparation was treated with NKCT1
(750 g ml−1)/GNP-NKCT1 (750 g ml−1) and spontaneous
contraction was recorded on a smoked drum by a lightly
sprung lever.
2.8.2.  Effect on isolated nerve muscle preparation
Isolated toad gastrocnemius sciatic (TGS) nerve was
prepared and suspended in frog Ringer’s solution (NaCl
154  mM,  KCl 5.6 mM,  CaCl2 2.2 mM,  NaHCO3 6 mM,  glucose
5.55  mM).  Isolated rat phrenic nerve diaphragm (RPND)
was  prepared after [35] and suspended in a 6 ml glass bath
containing oxygenated (95% O2 + 5% CO2) Tyrode’s solu-
tion.  Both the preparations were stimulated with a square
wave  electronic stimulator of 8 V, 0.5 ms  duration, 0.2 Hz
(Grass,  USA, Model No. SD9). TGS preparations were treated
with  NKCT1 (20 g ml−1) and GNP-NKCT1 (20 g ml−1),
RPND preparations were treated with NKCT1 (5 g ml−1)
and  GNP-NKCT1 (5 g ml−1) and contraction was recorded
with Brodie’s lever on a smoked kymograph paper.
2.8.3. Effect on isolated kidney tissue
Isolated rat kidney tissue (200 mg)  was collected from a
freshly  killed male albino rat and suspended in oxygenated
(95% O2 + 5% CO2) Kreb’s Ringer solution (3 ml)  in a glass
tissue bath at (37 ± 1 ◦C). NKCT1 (2 g ml−1)/GNP-NKCT1
(2 g ml−1) was added and incubated for 30 min. Incuba-
tion ﬂuid was  collected from control and treated tissue
bath  and immediately placed in ice (0 ◦C). The biochem-
ical markers (ALP, -GT) were measured by biochemical
kits (Merck, India). The kidney tissues were subjected to
histopathology study (as stated earlier).
2.9. In vivo acute toxicity study
2.9.1. Determination of absolute lethal dose
Absolute lethal dose (LD100) of NKCT1 and GNP-NKCT1
was  determined in Swiss albino male mice. Differ-
ent doses (1 mg  kg−1, 1.5 mg  kg−1, 2 mg  kg−1, 2.5 mg  kg−1,
2.75 mg  kg−1, 3 mg  kg−1 and 3.5 mg  kg−1) of NKCT1 and
GNP-NKCT1 were given to different animal groups (s.c.) and
mortality  was recorded up to 24 h of observation. The low-
est  dose that killed 100% of test animals was  considered as
the  LD100.
2.10.  In vivo sub-chronic toxicity study
Sub-chronic toxicity study was  done over a period of
15,  30 days in male albino Swiss mice (20 ± 2 g). The mice
were  divided into three groups: Group 1: sham control,
group 2: NKCT1 treated (2 g 100 g−1 day−1, i.p.) and group
3:  GNP-NKCT1 treated (2 g 100 g−1 day−1, i.p.) (n = 6). All
the  animals in groups 2 and 3 were treated for 15 and 30
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ays. Mortality, body weight, food and water intake, fae-
al  consistency of all the animals were monitored at 5 days
nterval.  Urine was collected from all groups of mice on
ay  30 and a qualitative analysis of urine parameters was
one  by Diastix reagent strips (Merck, India) and strip pho-
ograph  was recorded (Nikon D90, Nikon 105 mm f/2.8 VR
acro  lens).
.10.1. Haematology and serum biochemical parameters
Blood was collected from the control/treated animals
n day 15, and day 30 by cardiac puncture and stored
n  heparin vials. Total WBC, RBC count and haemoglobin
easurement were done. Serum was separated from the
lood  by centrifugation at 5000 rpm × 15 min. Serum bio-
hemical parameters (SGOT, SGPT, urea, creatinine, CK-MB,
DH)  were estimated by using biochemical kits (Merck,
ndia) and UV–vis spectrophotometer (Analab UV-180) in
he  kinetic mode as per the instruction manuals.
.10.2. Histopathology study
Kidney tissues of different groups of mice were collected
n  day 30 and dehydrated in graded alcohol (50%, 70%,
0%,  90% and 100%), cleared in xylene and embedded in
arafﬁn.  Sections (5 m)  were cut with rotary microtome
Weswox Optic, India), stained with haematoxylin–eosin,
nd observed under bright ﬁeld microscope (Motic BA
50,  Germany). Photographs were captured with Motic
oftware (Motic Image Plus 2.0 software) to observe micro-
copic  changes in the tissues.
.11. Statistical analysis
Data  were expressed as mean ± SEM (n = 6). The
epeated measure analysis of variance (ANOVA) was used
o  determine the signiﬁcant differences between groups.
 < 0.05 was considered to be statistically signiﬁcant.
. Result
.1. Puriﬁcation of NKCT1
NKCT1  from NKV was puriﬁed as stated by Debnath
t al. [3]. NKV was applied on CM-Cellulose column equili-
rate  with phosphate buffer (pH 7.2) and protein fractions
ere  eluted with NaCl gradient and further puriﬁed over
PLC.  Homogeneity of NKCT1 was checked by SDS-PAGE
nd SDS-molecular weight of the protein was found to be
.76  kDa.
.2.  Nanogold conjugation and characterization of
NP-NKCT1
Preparation of GNP-NKCT1 was done with sodium boro-
ydrate  reduction method by using NKCT1, GNP, PEG,
esulting in a light purple colour colloidal solution, stable
t  room temperature (25 ± 2 ◦C) and pH 7.2. Hydrodynamic
ize of GNP-NKCT1 determined by DLS was 68–122 nm
ith  an average of 92 nm.  Transmission electron micro-
cope image conﬁrmed the actual size of GNP as 5–25 nm,ports 1 (2014) 74–84 77
where  gold nanoparticles were arranged within the protein
(NKCT1) core [9].
3.3.  In vitro cellular toxicity study
3.3.1. Effect on rat blood lymphocyte
MTT assay showed 28 ± 3.1% and 8 ± 2.6% inhibition of
lymphocyte cell growth by NKCT1 (2 g ml−1) and GNP-
NKCT1 (2 g ml−1) as compared with untreated control
(Fig. 1A). Trypan blue exclusion assay revealed that there
were  32 ± 1.2% and 11 ± 1.7% decrease in lymphocyte count
by  NKCT1 (2 g ml−1) and GNP-NKCT1 (2 g ml−1) treat-
ment as compared to untreated control.
3.3.2. Effect on mouse peritoneal macrophage
MTT assay showed 38 ± 4.1% and 12 ± 1.5% inhibition
of cell growth by NKCT1 (2 g ml−1) and GNP-NKCT1
(2 g ml−1) respectively as compared with untreated con-
trol  (Fig. 1B). Trypan blue exclusion assay showed 34 ± 3.2%
and  11 ± 2% decrease in rat peritoneal macrophage
count by NKCT1 (2 g ml−1) and GNP-NKCT1 (2 g ml−1)
treatment respectively as compared with untreated
control.
3.3.3. Effect on rat peritoneal mast cell
NKCT1 (2 g ml−1) and GNP-NKCT1 (2 g ml−1) showed
30 ± 5% and 11 ± 2% degranulation of rat peritoneal mast
cells  respectively as compared with untreated control.
However, standard drug (Tramazac) showed 85 ± 6%
degranulation of mast cells, with respect to untreated con-
trol.
3.4.  In vitro tissue toxicity study
3.4.1. Effect on isolated guinea pig heart
NKCT1 (2 g ml−1) decreased the amplitude of the
contraction and heart rate leading to 100% irreversible
heart blockade within 40 ± 5 min, whereas GNP-NKCT1
(2 g ml−1) treatment showed 100% irreversible heart
blockade within 180 ± 10 min, which was  4.5-fold higher
than  that of NKCT1 (Fig. 2A and B).
3.4.2. Effect on isolated guinea pig auricle
NKCT1 (750 ng ml−1) decreased the amplitude of the
contraction leading to 50% blockade of isolated guinea
pig  auricle within 60 ± 3 min. GNP-NKCT1 (750 ng ml−1)
treatment showed 50% blockade within 180 ± 10 min,
which was 3-fold higher than that of NKCT1 (Fig. 2C and
D).
3.4.3.  Effect on isolated RPND preparation
NKCT1 (5 g ml−1) decreased the amplitude of con-
traction induced by electrical stimulation leading to 50%
neuromuscular blockade within 30 ± 2 min. GNP-NKCT1
(5 g ml−1) treatment showed 50% neuromuscular block-
ade within 180 ± 15 min, which was  6-fold higher than that
of  NKCT1 (Fig. 3A and B).3.4.4.  Effect on isolated TGS preparation
NKCT1 (20 g ml−1) decreased the amplitude of the
contraction induced by electrical stimulation leading to
78 P.P. Saha et al. / Toxicology Reports 1 (2014) 74–84
Fig. 1. Effect of NKCT1 and GNP-NKCT1 on normal rat lymphocyte, mouse peritoneal macrophage cells. Cell count by (A) MTT  assay and (B) by trypan blue
exclusion  assays. Each value represents quadruplicate samples of mean ± SEM. *P < 0.05 as compared to control.
eart, (CFig. 2. Effect of NKCT1 and GNP-NKCT1 on isolated guinea pig. (A and B) h
gastrocnemius  sciatic nerve. Time scale in minute.
50% neuromuscular blockade within 9 ± 2 min. GNP-NKCT1
(20  g ml−1) treatment showed 50% neuromuscular block-
ade  within 180 ± 15 min, which was 20-fold higher than
that  of NKCT1 (Fig. 3C and D). and D) auricle, (E and F) rat phrenic nerve diaphragm, and (G and H) toad
3.4.5. Effect on isolated rat kidney tissue
NKCT1 (2 g ml−1) signiﬁcantly increased ALP
(224.07 ± 18.9 U/L), released from kidney tissue, in
respect to untreated control tissue (32 ± 2.9 U/L). However
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gain, but no signiﬁcant loss of body weight as compared
with sham control group 1 mice (Fig. 4). NKCT1 treat-
ment signiﬁcantly reduced the food and water intake ofig. 3. Effect of NKCT1 and GNP-NKCT1 on isolated rat phrenic nerve dia
inute.
NP-NKCT1 (2 g ml−1) showed no signiﬁcant increase
n ALP (39.93 ± 6.15 U/L), released from kidney tis-
ue, in respect to untreated control tissue. NKCT1 and
NP-NKCT1 treatment signiﬁcantly increased -GT
73.24 ± 5.6 U/L and 43.26 ± 2.34 U/L), released from
idney tissue, in respect to untreated control tissue
26.34 ± 2.9 U/L). Histopathology study showed signiﬁcant
ecrotic effect of NKCT1 on kidney tissue, which was  not
bserved  in case of GNP-NKCT1 treated kidney tissue
Fig. 5).
.5.  In vivo acute toxicity study
The absolute lethal dose of GNP-NKCT1 was found to be
 mg  kg−1 (s.c.) in Swiss male albino mice, which was  about
-fold  than that of NKCT1 (1.5 mg  kg−1).
.6. In vivo sub-chronic toxicity study
.6.1. Effect on body weight, food and water intake,
aecal consistency, urine parameters
No mortality was recorded up to 30 days in all the
roups of mice. NKCT1 (2 g 100 g−1 day−1, i.p.) treat-
ent showed 22.2 ± 1.9% signiﬁcant decreases in body
eight in group 2 mice as compared with sham control
roup 1 mice. However GNP-NKCT1 (2 g 100 g−1 day−1, (A and B) and toad gastrocnemius sciatic nerve (C and D). Time scale in
i.p.)  treated group 3 animals showed slow body weightFig. 4. Effect of NKCT1 and GNP-NKCT1 on body weight gain of different
mice groups.
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Fig. 5. Effect of GNP-NKCT1 and NKCT1 on kidney tissue, in vivo and in vitro study. Tissue stained with haematoxylin and eosin. Original magniﬁcations
ntrol tis
notes co
ecrotic 10×.  (A–C) In vivo study with mice kidney tissue, where (A) denotes co
tissue.  (D–F) In vitro study with isolated rat kidney tissue, where (D) de
treated  tissue. Arrows (↑) indicated the increased glomerular space and n
the group 2 mice after day 5 in respect to control group
1  and GNP-NKCT1 treated group 3 mice. Semisolid fae-
cal  pellets were observed by NKCT1 treated group 2 mice
after  day 9, whereas GNP-NKCT1 treated group 3 mice
and  sham control group 1 mice showed solid faecal pel-
lets.Urine  strip test on day 30 revealed no changes in urinary
glucose, bilirubin, ketone, speciﬁc gravity, blood, pH, uro-
bilinogen  in NKCT1 as well as GNP-NKCT1 treated groups 2
and  3 mice. However, urine of the NKCT1 treated groupsue; (B) denotes NKCT1 treated tissue; (C) denotes GNP-NKCT1 treated
ntrol tissue; (E) denotes NKCT1 treated tissue; (F) denotes GNP-NKCT1
effect of NKCT1.
2  mice showed high level of protein (+++) as compared
with GNP-NKCT1 treated group 3 mice urine protein
(+).
3.6.2. Effect on haematological parameters
On day 15, there were no signiﬁcant changes in totalRBC, WBC  and haemoglobin level in NKCT1 and GNP-
NKCT1 treated groups of mice. On day 30, there was  a
signiﬁcant increase in WBC  count that was  observed in
NKCT1  (79.2 ± 2.7%) and GNP-NKCT1 (32.4 ± 1.6%) treated
ology Reports 1 (2014) 74–84 81
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roups 2 and 3 mice in respect to sham control group 1
ice  (Table 1).
.6.3.  Effect on serum biochemical parameters
On day 15, there was  a signiﬁcant increase in serum
GPT, urea, creatinine, CK-MB and LDH levels (40.7 ± 2.94%,
2.14  ± 2.36, 62.36 ± 1.31%, 80.94 ± 1.43 and 21.3 ± 1.7%
espectively) due to NKCT1 treatment in group 2 mice
s  compared with sham control group 1 mice. However
o  signiﬁcant change in serum SGPT, urea, creatinine, CK-
B  and LDH was observed after GNP-NKCT1 treatment in
roup  3 mice as compared with sham control group 1 mice
Table  1).
On  day 30, serum SGPT, urea, creatinine, CK-MB and LDH
evels  showed (18.12 ± 1.29%, 127.82 ± 2.14%, 102.5 ± 4.1%,
6.1  ± 1.39% and 49.27 ± 2.37%) signiﬁcant increase after
KCT1  treatment in group 2 mice as compared with sham
ontrol  group 1 mice. Serum urea, creatinine, and LDH
evels (23.5 ± 1.39%, 20.21 ± 1.7%, and 14.7 ± 1.37%) were
lso  signiﬁcantly increased after GNP-NKCT1 treatment in
roup  3 mice in compared with sham control group 1 mice.
he  degree of increase was NKCT1 > GNP-NKCT1 (Table 1).
.6.4. Effect on kidney histology
After  30 days, NKCT1 treated kidney tissue showed par-
ial  tubular and glomerular necrosis and increased capsular
pace.  No such detrimental changes in kidney tissue of
roup  3 mice were observed after GNP-NKCT1 treatment
Fig. 5).
.  Discussion
Biomedical research using natural resources has identi-
ed  animal venoms and toxins with great potential against
arious pathophysiological conditions. A major drawback
f  these bioactive toxin molecules is their toxicity, which
imits  their application in drug development process. Sev-
ral  attempts have been made to reduce the toxicity
f these molecules, nanoconjugation being one of them.
anoconjugation of therapeutically active toxin molecules
ill  not only provide a mechanism for increasing their
fﬁcacy but also decreases toxicity. For instance, it was
eported that mellitin from bee venom and bombesin from
oad  skin were conjugated to PFC and gold nanoparticles
espectively which increased their selective delivery and
ellular  uptake in cancer cells, which limit their nonspeciﬁc
ff  target toxicity [14,15]. Methotrexate (MTX) is clinically
sed  as anti-arthritic and an anti-folate agent that is often
ssociated with toxicity [22]. Gomes et al. [23] showed that
anogold  conjugation with MTX  (MTX-GNP) increased its
nti-arthritic potential.
In  vitro cellular toxicity studies showed that GNP-
KCT1 possesses about 3-fold less toxic effect on rat
lood lymphocytes than that of NKCT1, as observed by
TT  and trypan blue exclusion assay. Macrophages are
he  white blood cells produced by the division of mono-
ytes, phagocytic in nature and acting in both non-speciﬁc
innate immunity) and speciﬁc defence mechanism (adap-
ive  immunity). Trypan blue exclusion and MTT  assay
howed that NKCT1 (2 g ml−1) killed 40–46% peritoneal
acrophage cell population after 24 h incubation, whereas Ta
b
le
 
1
Se
ru
m
 
bi
oc
h
e
15
 
d
ay
s
30
 
d
ay
s
D
at
a 
re
p
re
se
n
*
P 
< 
0.
05
 
c
ology Re82 P.P. Saha et al. / Toxic
GNP-NKCT1 showed only 11–12% macrophage cell killing
property. These data indicated that the adverse toxicity
of  NKCT1 on macrophage cell was signiﬁcantly reduced
(about 3-fold) after GNP conjugation. It was very likely with
that  PEGylgted gold nanoparticles conjugation with a snake
venom  protein toxin NKCT1 reduced its toxicity on human
lymphocytes [9].
Mast  cells mediate inﬂammatory responses such as
hypersensitivity and allergic reactions. It stores a num-
ber  of chemical mediators including histamine, interlukins,
proteoglycans and various enzymes. Upon stimulation,
mast cells release the chemical mediators that produce
local allergic and inﬂammatory responses. Degranulation
of mast cell is a common effect of toxin molecules. Toxin
SA-HT isolated from butter ﬁsh venom [24], a basic PLA2
isolated from Trimeresurus mucrosquamata snake venom
[25],  produced oedema and increased capillary permeabil-
ity  by mast cell degranulation. In the present study, it was
found  the NKCT1 (2 g ml−1) showed 30% degranulation of
rat  peritoneal mast cells, which was signiﬁcantly reduced
(3-folds) in the case of GNP-NKCT1 treatment. Thus GNP
conjugation reduced the mast cell degranulation property
as  well as the pro-inﬂammatory effect of the NKCT1.
Cardiotoxicity is very common with snake venom tox-
ins  (NKCT1 and NN-32). In vitro cardiotoxicity on isolated
heart  and auricle preparation revealed that GNP-NKCT1
increased the blockage time of heart and auricle (4.5- and
3-folds  respectively) than that of NKCT1. Protection against
NKCT1  induced cardiotoxicity was further supported by
serum  levels of heart injury markers (CK-MB, LDH) in
in  vitro model. CK-MB helps to reserve energy through cre-
atine  phosphate and produce ATP as per requirement of
the  body. During the acute myocardial infarction, serum
CK-MB level increased due to the release of intracellular
CK-MB [26]. Lactate Dehydrogenase catalyzes the conver-
sion  of pyruvate to lactate. Patient with acute myocardial
infarction, serum LDH level exceeds the normal range and
reaches  a peak elevation of two to three folds in 3–5
days [27]. Serum CK-MB and LDH level were increased
due to NKCT1 treatment after 15 and 30 days in respect
to  sham control. This was likely due to myocardial dam-
age  induced by NKCT1. Animals exposed to GNP-NKCT1
showed no signiﬁcant changes in serum CK-MB level after
15  days and 30 days treatment. No signiﬁcant change in
serum  LDH level was observed after 15 days treatment with
GNP-NKCT1. However after 30 days, animals exposed to
GNP-NKCT1 showed a signiﬁcant increase in serum LDH
level  (17.1 ± 1.6%), in respect to sham control mice. But
increased serum LDH level in group 3 mice, after 30 days
exposure to GNP-NKCT1, was signiﬁcantly (22 ± 1.7%) low
in  respect to NKCT1 treated group 2 mice. The above ﬁnd-
ings  indicated that GNP conjugation signiﬁcantly reduces
the  cardiotoxicity of NKCT1.
Nephrotoxicity  is one of the major characteristics of the
snake  venom molecules. Among the several nephrotoxicity
markers, -glutamyl transpeptidase (-GT), a glycoprotein,
attached to the external surface of various cell types. In
the  kidney, the primary site of -GT activity is the outer
surface of the microvillus membrane (brush border) in
the  proximal tubular cells [28]. High enzyme activity of
alkaline  phosphates (ALP) was also found in the cells ofports 1 (2014) 74–84
proximal convoluted tubules [29]. -GT and ALP were con-
sidered  as biomarkers for detecting renal tubular injury.
The  increased activity of these biomarkers, detected in
urine  and serum shortly after tubular injury, indicated
their release from proximal tubular cells and suggested to
predict  acute renal failure. In the present study, we have
observed that NKCT1 increased the release of APL and -
GT  from isolated rat kidney tissue. It is likely that NKCT1
acted on the PT cells and increased the release of ALP
and -GT. GNP-NKCT1 treatment decreased the release of
ALP  (82.2 ± 2%) and -GT (40.93 ± 1.3%), as compared with
NKCT1  treatment, indicated that GNP conjugation signiﬁ-
cantly  reduced the nephrotoxic property of NKCT1. NKCT1
treatment signiﬁcantly increased the serum urea, creati-
nine  level. In case of GNP-NKCT1 treated mice there was
no  sign of increase in serum creatinine and urea level
till  day 15. However signiﬁcant increase (19.3 ± 2.1% and
23  ± 1.8%) of serum creatinine and urea level in group 3
mice,  in respect to sham control mice, was observed after
30  days treatment with GNP-NKCT1. The data provided in
Table  1 clearly showed that increased serum creatinine and
urea  level in animals exposed to GNP-NKCT1 and NKCT1
after  30 days, were in the order of NKCT1 > GNP-NKCT1.
That indicated the reduced nephrotoxic effect of NKCT1
after  its GNP conjugation.
Toxicity  of NKCT1 was reduced due to nanogold conju-
gation which was  observed in in vitro cellular and organ
toxicity as well as in in vivo LD100 and sub-chronic toxicity
studies. The reduced toxicity of GNP-NKCT1 may  be due to
its  less bioavailablity, because body recognizes hydropho-
bic  GNP as foreign particle and the reticulo-endothelial
system eliminates these from the blood stream and takes
them  up in the liver or the spleen or internalized by
macrophages [30]. In the present investigation, GNP was
coated  with PEG during the preparation of GNP-NKCT1,
which shifted the overall particle charge to the positive
site by surface modiﬁcation, thus blocking the electrostatic
and hydrophobic interactions, which helped to prevent the
internalization of GNP-NKCT1 by phagocytosis through the
binding  of opsonin proteins to particle surfaces. As a result
it  increased the bioiavailability of GNP-NKCT1 and also pre-
vented  agglomeration in in vivo system.
NKCT1 is a 6.76 kDa protein with single polypeptide
chain having 60 amino acid residues. The amino acid
sequence of the NKCT1 is “LKCNKLVPLF YKTCPAGKNL
CYKMFMVSNK TVPVKRGCID VCPKNSLVLK YVCCNTDRCN”.
It possesses 4 intra molecular disulﬁde bonds (Uniport,
entry name CX1 NAJKA, accession P0CH80). It has struc-
tural  and functional similarity of 3 ﬁnger toxins isolated
from cobra venom. 3FTXs consist of one polypeptide chain,
their  spatial structure being characterized by a hydropho-
bic  core stabilized by four disulﬁde bridges, which conﬁne
three  polypeptide loops (ﬁngers). In cobra venom 3FTXs
are  represented mainly by -neurotoxins and cytotox-
ins. 3FTXs neurotoxins use a number of amino acid
residues, including Lys23/27/49/4, Asp27/Asp31, Trp25/29,
Phe29/32, Cys26/30 to bind with Torpedo as well as ˛7
receptor [31,32]. Along with Asp, Trp, Phe the amino acid
Lysne  and Cystine residues of the 3FTXs are essential for
binding  to nAChRs. It was  also well established that Lysine
and  Cysteine have great afﬁnity to bind with nanogold.
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ysine binds with the gold nanoparticles surface through
t’s  -amine group ( NH3+) with GNP surface whereas the
inding of Cystein to GNP is mediated by covalent inter-
ction through Thiol group (SH) associated with Cystine
esidues [33,34]. Therefore it may  be assumed that the neu-
otoxicity  of NKCT1 depends on the binding of its Lysine
nd  Cystine residues to the nACh receptors and possibly
NP reduced the neurtoxicity of NKCT1 by altering its nACh
peciﬁcity  through binding to its Lysine or Cystine amino
cid  residues.
Previous research on 3FTXs reported that the myotoxic
ctivity is a reﬂection of the myotoxic site of 3FTXs
yotoxins, which contained a cationic segment ﬂanking
 hydrophobic region. Particularly the myotoxic region in
ardiotoxins is located on all three loops with a row of
ositively charged Lysine residues [31]. This is a potent
inding site for GNP, located at the top end of the NKCT1
nd  other 3FTXs. It was observed through CD spectra anal-
sis  of GNP-NKCT1 that GNP conjugation results in 20.5%
ncrease in alpha helix, 5.5% increase in -sheets and 32%
f  -turn instead of random coil in NKCT1 [9]. The struc-
ural alteration of the NKCT1 after GNP conjugation may
e  responsible for the reduction of its toxicity proﬁle. The
xact  molecular mechanism responsible for the reduction
f  the toxicity of NKCT1 is still not clear. Further studies on
his  area are warranted for the understanding of molecular
echanism related to the reduction of toxicity proﬁle of
he  GNP-NKCT1 and its future applications.
. Conclusion
It  may  be concluded that gold nanoparticle conjuga-
ion reduced the toxicity of snake venom protein toxin
KCT1. This work will deﬁnitely enlighten the opportuni-
ies of reducing toxicities of bioactive toxin molecules by
anoconjugation.
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